EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

This study is testing EIK1005 — a new drug that targets a protein called Werner Helicase involved in DNA repair — alone and in combination with pembrolizumab (an immunotherapy drug), in patients with advanced solid tumors, with a focus on tumors that have a specific instability in their DNA repair system called MSI-H or dMMR. **You may be eligible if...** - You are 18 or older - You have confirmed advanced (unresectable or metastatic) solid tumor cancer - Your life expectancy is at least 3 months - For some parts: your tumor has confirmed MSI-H or mismatch repair deficient (dMMR) status - You have archival tumor tissue available **You may NOT be eligible if...** - You have had prior treatment with pembrolizumab or similar drugs with severe adverse effects - You have significant immune system disorders or require immune-suppressing medications - Your organ function is below required thresholds Talk to your doctor to see if this trial is right for you.